TABLE 1

Proportional prevalence of anti-tuberculosis drug-resistance in the International Carbapenems Study Group cohort

CohortFluoroquinolonesClofazimineEthambutolPyrazinamideProthionamideKanamycin
International Carbapenems Study Group
 New cases#30/140
21.4% (14.6–28.2)
90/140
64.3% (56.4–72.2)
81/130
62.3% (53.9–70.6)
60/137
43.8% (35.5–52.1)
19/84
22.6% (13.7–31.5)
 Previously-treated tuberculosis cases107/195
54.9% (47.9–61.9)
140/197
71.1% (64.8–77.4)
113/169
66.9% (59.8–74.0)
113/176
64.2% (57.1–71.3)
80/140
57.1% (48.9–65.3)
 All cases137/336
40.8% (35.6–46.1)
232/339
68.4% (63.5–73.4)
195/300
65.0% (59.6–70.4)
174/314
55.4% (49.9–60.9)
100/225
44.4% (37.9–50.9)
Stratification by geographical region
 International Carbapenems Study Group Europe
  Previously-treated tuberculosis cases61/142
43.0% (34.9–51.1)
103/142
72.5% (65.2–79.8)
83/124
66.9% (58.6–75.2)
89/141
63.1% (55.1–71.1)
44/87
50.6% (40.1–61.1)
  All cases91/283
32.2% (26.8–37.6)
195/284
68.7% (63.3–74.1)
165/255
64.7% (58.8–70.6)
150/279
53.8% (48.0–59.7)
64/172
37.2% (30.0–44.4)
 International Carbapenems Study Group South America
  Previously-treated tuberculosis cases46/53
86.8% (77.7–95.9)
37/55
67.3% (54.9–79.7)
30/45
66.7% (52.9–80.5)
24/35
68.6% (53.2–84.0)
36/53
67.9% (55.3–80.5)
  All cases46/53
86.8% (77.7–95.9)
37/55
67.3% (54.9–79.7)
30/45
66.7% (52.9–80.5)
24/35
68.6% (53.2–84.0)
36/53
67.9% (55.3–80.5)
Control
 International Carbapenems Study Group control group
  New cases (108/168)15/105
14.3% (7.6–21.0)
61/105
58.1% (48.7–67.5)
53/96
55.2% (45.3–65.1)
35/103
34.0% (24.9–43.1)
7/56
12.5% (3.8–21.2)
  Previously-treated tuberculosis cases (59/168)12/56
21.4% (10.7–32.1)
30/58
51.7% (38.9–64.6)
20/45
44.4% (29.9–58.9)
28/56
50.0% (36.9–63.1)
9/32
28.1% (12.5–43.7)
  All cases27/161
16.8% (11.0–22.6)
92/164
56.1% (48.5–63.7)
73/141
51.8% (43.6–60.0)
63/159
39.6% (32.0–47.2)
16/88
18.2% (10.1–26.3)
  • Data are presented as number of resistant cases for a specific drug/total number of cases tested for a specific drug and % proportional resistance (95% CI). #: Out of 145 total new cases, 144 cases were from Europe. Susceptibility to all drugs in the International Carbapenems Study Group was found only in the control group: 14 cases were susceptible to all six drugs out of 168 controls. No data were available for clofazimine.